Literature DB >> 27933957

Synthesis and Antiviral Evaluation of Octadecyloxyethyl Benzyl 9-[(2-Phosphonomethoxy)ethyl]guanine (ODE-Bn-PMEG), a Potent Inhibitor of Transient HPV DNA Amplification.

James R Beadle1, Nadejda Valiaeva1, Guang Yang2, Jei-Hwa Yu2, Thomas R Broker2, Kathy A Aldern1, Emma A Harden2, Kathy A Keith2, Mark N Prichard2, Tracy Hartman3, Robert W Buckheit3, Louise T Chow2, Karl Y Hostetler1,4.   

Abstract

Human papillomavirus (HPV) high-risk genotypes such as HPV-16 and HPV-18 cause the majority of anogenital tract carcinomas, including cervical cancer, the second most common malignancy in women worldwide. Currently there are no approved antiviral agents that reduce or eliminate HPV and reverse virus-associated pathology. We synthesized and evaluated several alkoxyalkyl acyclic nucleoside phosphonate diesters and identified octadecyloxyethyl benzyl 9-[(2-phosphonomethoxy)ethyl]guanine (ODE-Bn-PMEG) as an active compound which strongly inhibited transient amplification of HPV-11, -16, and -18 origin-containing plasmid DNA in transfected cells at concentrations well below its cytotoxic concentrations. ODE-Bn-PMEG demonstrated increased uptake in human foreskin fibroblast cells and was readily converted in vitro to the active antiviral metabolite, PMEG diphosphate. The P-chiral enantiomers of ODE-Bn-PMEG were obtained and appeared to have equivalent antiviral activities against HPV. ODE-Bn-PMEG is a promising candidate for the local treatment of HPV-16 and HPV-18 and other high-risk types, an important unmet medical need.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27933957     DOI: 10.1021/acs.jmedchem.6b00659

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Octadecyloxyethyl benzyl tenofovir: A novel tenofovir diester provides sustained intracellular levels of tenofovir diphosphate.

Authors:  James R Beadle; Kathy A Aldern; Xing-Quan Zhang; Nadejda Valiaeva; Karl Y Hostetler; Robert T Schooley
Journal:  Antiviral Res       Date:  2019-09-21       Impact factor: 5.970

2.  Evaluation of ODE-Bn-PMEG, an acyclic nucleoside phosphonate prodrug, as an antiviral against productive HPV infection in 3D organotypic epithelial cultures.

Authors:  N Sanjib Banerjee; Hsu-Kun Wang; James R Beadle; Karl Y Hostetler; Louise T Chow
Journal:  Antiviral Res       Date:  2017-12-26       Impact factor: 5.970

3.  Human Papillomavirus (HPV) Entry Inhibitors.

Authors:  Yun Zhu
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 4.  In vitro methods for testing antiviral drugs.

Authors:  Michaela Rumlová; Tomáš Ruml
Journal:  Biotechnol Adv       Date:  2017-12-29       Impact factor: 14.227

5.  In silico screening and molecular dynamics simulations toward new human papillomavirus 16 type inhibitors.

Authors:  Nima Razzaghi-Asl; Sahar Mirzayi; Karim Mahnam; Vahed Adhami; Saghi Sepehri
Journal:  Res Pharm Sci       Date:  2022-01-15

6.  A novel lipid prodrug strategy for sustained delivery of hexadecyloxypropyl 9-[2-(phosphonomethoxy)ethyl]guanine (HDP-PMEG) on unwanted ocular proliferation.

Authors:  Mei Chen; Jiangping Hou; Guilin Tan; Peng Xie; William R Freeman; James R Beadle; Karl Y Hostetler; Lingyun Cheng
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.